Triangle Securities Wealth Management Sells 196 Shares of Bristol-Myers Squibb (NYSE:BMY)

Triangle Securities Wealth Management cut its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,456 shares of the biopharmaceutical company’s stock after selling 196 shares during the quarter. Triangle Securities Wealth Management’s holdings in Bristol-Myers Squibb were worth $2,335,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Penserra Capital Management LLC bought a new position in shares of Bristol-Myers Squibb during the second quarter worth approximately $27,000. Horan Securities Inc. increased its stake in Bristol-Myers Squibb by 217.3% in the second quarter. Horan Securities Inc. now owns 441 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. PNC Managed Account Solutions Inc. bought a new position in Bristol-Myers Squibb in the second quarter valued at approximately $37,000. Regency Capital Management Inc. DE bought a new position in Bristol-Myers Squibb in the first quarter valued at approximately $43,000. Finally, Cypress Point Wealth Management LLC bought a new position in Bristol-Myers Squibb in the second quarter valued at approximately $48,000. 72.07% of the stock is currently owned by institutional investors.

Shares of NYSE:BMY opened at $56.81 on Thursday. The firm has a market cap of $126.10 billion, a PE ratio of -23.67, a price-to-earnings-growth ratio of 1.08 and a beta of 0.61. The firm’s fifty day moving average is $58.78 and its 200-day moving average is $63.83. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.36 and a current ratio of 1.47. Bristol-Myers Squibb has a 52 week low of $56.11 and a 52 week high of $69.75.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Tuesday, October 26th. The biopharmaceutical company reported $2.00 EPS for the quarter, topping analysts’ consensus estimates of $1.92 by $0.08. The company had revenue of $11.62 billion for the quarter, compared to analyst estimates of $11.52 billion. Bristol-Myers Squibb had a negative net margin of 11.89% and a positive return on equity of 43.05%. Bristol-Myers Squibb’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.63 earnings per share. Sell-side analysts forecast that Bristol-Myers Squibb will post 7.52 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, November 1st. Investors of record on Friday, October 1st were issued a $0.49 dividend. The ex-dividend date of this dividend was Thursday, September 30th. This represents a $1.96 annualized dividend and a yield of 3.45%. Bristol-Myers Squibb’s payout ratio is -81.67%.

A number of research analysts recently issued reports on BMY shares. Morgan Stanley decreased their price objective on shares of Bristol-Myers Squibb from $71.00 to $66.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 12th. BMO Capital Markets started coverage on shares of Bristol-Myers Squibb in a research note on Thursday, November 18th. They issued an “outperform” rating and a $72.00 price objective on the stock. TheStreet raised shares of Bristol-Myers Squibb from a “c+” rating to a “b” rating in a research note on Wednesday, November 17th. Truist began coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, July 28th. They issued a “buy” rating and a $74.00 price objective on the stock. Finally, Barclays decreased their target price on shares of Bristol-Myers Squibb from $68.00 to $66.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 28th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $69.20.

In related news, CEO Giovanni Caforio sold 25,000 shares of the business’s stock in a transaction on Monday, September 20th. The shares were sold at an average price of $60.64, for a total value of $1,516,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Autenried Paul Von sold 18,363 shares of the business’s stock in a transaction on Monday, November 22nd. The shares were sold at an average price of $57.17, for a total transaction of $1,049,812.71. The disclosure for this sale can be found here. In the last 90 days, insiders sold 60,716 shares of company stock worth $3,553,545. 0.11% of the stock is owned by company insiders.

Bristol-Myers Squibb Profile

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Featured Article: Dividend Yield

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.